RA Session II, Taysha Gene Therapies CEO
Prelude to buyout? Astellas picks up Taysha stock, two gene therapy programs for $50M
Half a year after Taysha Gene Therapies laid off 35% of its staffers and paused the bulk of its R&D work, the Dallas crew has …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
